Overview
- Cardinal Health raised its fiscal 2026 adjusted earnings guidance to $10.70–$10.80 per share, up from $10.15–$10.35.
- Adjusted earnings per share reached $3.17 for the quarter, topping the $2.79 Wall Street estimate.
- Total revenue rose 11% to $60.9 billion but missed the $62.1 billion forecast as pass‑through drug pricing lowered reported sales without hurting margins.
- Net earnings declined to $399 million from $506 million due to a $184 million pretax goodwill impairment linked to the Integrated Oncology Network acquisition.
- Shares gained about 1.6% in premarket trading after Evercore ISI called the quarter solid and said the sales shortfall reflected pricing pass‑through rather than operational weakness.